PT -期刊文章盟Ramanathan Sudarshini AU -克里斯蒂娜测前盟——伊丽莎白·巴恩斯盟以斯帖Tantsis AU -斯蒂芬Reddel盟-安德鲁·亨德森盟Ostoja Vucic AU -马克戈尔曼AU -莱斯利·本森盟Gulay高山赖尼盟盟-凯瑟琳-迈克尔·巴内特AU -约翰Parratt AU -托德·哈迪AU -理查德·莱维盟-维拉Merheb AU -玛格丽塔Nosadini AU -冯国经盟Fabienne Brilot AU -拉塞尔戴尔TI -髓少突细胞糖蛋白抗体与双边和复发性视神经炎和多发性硬化症有不同的辐射资料或Aquaporin-4 Antibody-associated视神经炎(P3.001) DP - 2016年4月05 TA -神经病学PG - P3.001 VI - 86 IP - 16补充4099 - //www.ez-admanager.com/content/86/16_Supplement/P3.001.short 4100 - //www.ez-admanager.com/content/86/16_Supplement/P3.001.full所以Neurology2016 4月05;首页86 AB -目的:我们进行第一集视神经炎的临床和放射学描述(上)患者髓少突细胞糖蛋白antibody-associated (MOG-ON), aquaporin-4 antibody-associated (AQP4-ON),和多发性硬化症(毫秒)。我们提出会有特定的放射性预测根据的原因。背景:早期识别的病因和预后影响治疗决策。设计/方法:我们进行了以流式细胞术测定使用HEK293细胞表达完整的人类生活MOG测试血清23成人AQP4 antibody-negative neuromyelitis视谱系障碍。蒙蔽neuroradiological评估随后进行磁共振成像的50个患者(平均年龄24岁,射程3-58,41岁女性)的第一集,包括MOG-ON (n = 19), AQP4-ON (n = 11),毫秒(n = 13)和非保密(n = 7)。结果:MOG抗体检测在9/23的病人,他们举行了双边。MOG-ON患者更有可能复发,是类固醇响应。两国参与在MOG-ON更为常见,AQP4-ON比毫秒(84 v (percnt)。82 (percnt) 23节[percnt]),视神经头部肿胀更常见于MOG-ON (53 percnt v。9 [percnt] v.0 [percnt]),交叉的更为普遍参与AQP4-ON (5 v (percnt)。64[percnt] v.15[percnt]), and bilateral optic tract involvement was more common in AQP4-ON (0[percnt] v.45[percnt] v.0[percnt]). Retrobulbar optic nerve involvement was more common in MOG-ON, whereas intracranial optic nerve involvement was more common in AQP4-ON. MOG-ON and AQP4-ON had longer lesion lengths and lesion extent scores than MS-ON. AQP4-ON more frequently had severe and sustained visual impairment. Conclusions: MOG antibodies are associated with a bilateral ON phenotype and are steroid responsive. MOG and AQP4-ON are frequently bilateral and longitudinally extensive, compared with MS-ON. MOG-ON tends to involve the anterior optic pathway whereas AQP4-ON tends to involve the posterior optic pathway. These radiological predictors may expedite diagnosis at the first presentation of ON, with therapeutic and prognostic implications.Disclosure: Dr. Ramanathan has received personal compensation from NHMRC Australia and the Petre Foundation. Dr. Prelog has nothing to disclose. Dr. Barnes has nothing to disclose. Dr. Tantsis has nothing to disclose. Dr. Reddel has received research support from Genzyme Sanofi, Biogen, CSL, and Baxter. Dr. Henderson has nothing to disclose. Dr. Vucic has received research support from Biogen Idec, Novartis, Bayer, CSL, and Genzyme. Dr. Gorman has nothing to disclose. Dr. Benson has nothing to disclose. Dr. Alper has nothing to disclose. Dr. Riney has received research support from Novartis. Dr. Barnett has received research support from Novartis Pharmaceuticals. Dr. Parratt has received research support from Multiple Sclerosis Research Australia, Genzyme, Novartis, Merck Serono and Bayer Schering, Biogen Idec and CSL. Dr. Hardy has nothing to disclose. Dr. Leventer has nothing to disclose. Dr. Merheb has nothing to disclose. Dr. Nosadini has nothing to disclose. Dr. Fung has nothing to disclose. Dr. Brilot-Turville has received research support from Star Scientic Foundation, Trish MS Research Foundation, MSRA, MS Angels Melbourne, NHMRC, and the Petre Foundation. Dr. Dale has received research support from Star Scientific Foundation, Trish MS Research Foundation, MSRA, NHMRC Australia, and the Petre Foundation.Monday, April 18 2016, 8:30 am-7:00 pm